Testosterone signaling is widely considered to be mediated through the transcription-regulating intracellular androgen receptor (iAR). In the human prostate cancer cell line LNCaP we demonstrated the presence of unconventional membrane receptors for testosterone (mAR) besides the classic iAR. Binding sides for testosterone on the surface of LNCaP cells were clearly revealed with the membrane-impermeable testosterone-BSA-FITC by confocal laser-scanning microscopy and flow cytometry. Furthermore, we found that testosterone was able to induce a rapid activation of extracellular signal-related kinase 1 and 2 (ERK1/2), but not altered p38 MAPK and c-jun N-terminal kinase (JNK) activity. The testosterone-induced phosphorylation of ERK1/2 could not be inhibited by the AR antagonist cyproterone, excluding the involvement of iAR. Consistent with this finding, the impeded testosterone-BSA was also capable of rapidly phosphorylating ERK1/2, further revealing membrane receptor being responsible for the activation of ERK1/2. Additionally, testosterone-BSA induced a transient expression of c-Fos, which was in a timescale consistent with the rapid ERK1/2 phosphorylation and could be blocked by ERK1/2 inhibitor PD098059, suggesting an ERK1/2-dependent mechanism. Together, these data demonstrated a novel mode of testosterone signaling on LNCaP cells which was not mediated through the classical androgen receptor response, but through unconventional membrane receptors.

Keywords:
Testosterone, Androgen receptor, Rapid effect, Mitogen-activated protein kinases, LNCaP cells
This content is only available via PDF.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.